Literature DB >> 15388469

In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations.

Samuel A Shelburne1, Daniel M Musher, Kristina Hulten, Heather Ceasar, Michael Y Lu, Imran Bhaila, Richard J Hamill.   

Abstract

This study employs time-kill techniques to examine the most common drug combinations used in the therapy of methicillin-resistant Staphylococcus aureus (MRSA) infections, vancomycin plus either gentamicin or rifampin. Community-associated MRSA were more likely to be synergistically inhibited by combinations of vancomycin and gentamicin versus vancomycin alone compared to inhibition associated with hospital-acquired strains.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15388469      PMCID： PMC521878          DOI： 10.1128/AAC.48.10.4016-4019.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  A novel methicillin-resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds.

Authors:  Robert S Daum; Teruyo Ito; Keiichi Hiramatsu; Farid Hussain; Kanokporn Mongkolrattanothai; Mantana Jamklang; Susan Boyle-Vavra
Journal:  J Infect Dis       Date:  2002-10-03       Impact factor: 5.226

2.  Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community.

Authors:  Keiko Okuma; Kozue Iwakawa; John D Turnidge; Warren B Grubb; Jan M Bell; Frances G O'Brien; Geoffrey W Coombs; John W Pearman; Fred C Tenover; Maria Kapi; Chuntima Tiensasitorn; Teruyo Ito; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

3.  Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998.

Authors:  T S Naimi; K H LeDell; D J Boxrud; A V Groom; C D Steward; S K Johnson; J M Besser; C O'Boyle; R N Danila; J E Cheek; M T Osterholm; K A Moore; K E Smith
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

4.  A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus.

Authors:  Y Katayama; T Ito; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 5.  The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus.

Authors:  G A Ayliffe
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

6.  Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin.

Authors:  J Fortún; E Navas; J Martínez-Beltrán; J Pérez-Molina; P Martín-Dávila; A Guerrero; S Moreno
Journal:  Clin Infect Dis       Date:  2001-06-05       Impact factor: 9.079

Review 7.  Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus--an emerging problem for the management of skin and soft tissue infections.

Authors:  E Anne Eady; Jonathan H Cove
Journal:  Curr Opin Infect Dis       Date:  2003-04       Impact factor: 4.915

8.  Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus.

Authors:  Laurel S Almer; Virginia D Shortridge; Angela M Nilius; Jill M Beyer; Niru B Soni; Mai H Bui; Gregory G Stone; Robert K Flamm
Journal:  Diagn Microbiol Infect Dis       Date:  2002-07       Impact factor: 2.803

9.  A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance.

Authors:  Feng-Yee Chang; Brent B MacDonald; James E Peacock; Daniel M Musher; Patricia Triplett; Joseph M Mylotte; Alice O'Donnell; Marilyn M Wagener; Victor L Yu
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

10.  Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence.

Authors:  Francois Vandenesch; Timothy Naimi; Mark C Enright; Gerard Lina; Graeme R Nimmo; Helen Heffernan; Nadia Liassine; Michèle Bes; Timothy Greenland; Marie-Elisabeth Reverdy; Jerome Etienne
Journal:  Emerg Infect Dis       Date:  2003-08       Impact factor: 6.883
View more
  12 in total

Review 1.  Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection.

Authors:  M H Kollef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

2.  Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: A perspective for Canadian health care practitioners.

Authors:  Michelle Barton; Michael Hawkes; Dorothy Moore; John Conly; Lindsay Nicolle; Upton Allen; Nora Boyd; Joanne Embree; Liz Van Horne; Nicole Le Saux; Susan Richardson; Aideen Moore; Dat Tran; Valerie Waters; Mary Vearncombe; Kevin Katz; J Scott Weese; John Embil; Marianna Ofner-Agostini; E Lee Ford-Jones
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

3.  A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosides.

Authors:  Nishad Thamban Chandrika; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2015-11-19       Impact factor: 3.597

4.  Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia.

Authors:  G Luo; B Spellberg; T Gebremariam; H Lee; Y Q Xiong; S W French; A Bayer; A S Ibrahim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-01       Impact factor: 3.267

5.  In vitro and in vivo evaluations of oxacillin efficiency against mecA-positive oxacillin-susceptible Staphylococcus aureus.

Authors:  Alexandros Ikonomidis; George Michail; Afroditi Vasdeki; Maria Labrou; Vasilis Karavasilis; Constantinos Stathopoulos; Antonios N Maniatis; Spyros Pournaras
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

6.  Health care-associated endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.

Authors:  Chia-Yu Chi; Tsai-Ling Lauderdale; Shih-Min Wang; Jing-Ming Wu; Yu-Jen Yang; Ching-Chuan Liu
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

7.  Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus.

Authors:  David J Riedel; Elizabeth Weekes; Graeme N Forrest
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

8.  Aminoglycoside-resistance mechanisms in multidrug-resistant Staphylococcus aureus clinical isolates.

Authors:  R Kelmani Chandrakanth; S Raju; S A Patil
Journal:  Curr Microbiol       Date:  2008-03-05       Impact factor: 2.188

9.  Once-daily gentamicin administration for community-associated methicillin resistant Staphylococcus aureus in an in vitro pharmacodynamic model: preliminary reports for the advantages for optimizing pharmacodynamic index.

Authors:  Sun Woo Kim; Dong-Gun Lee; Su-Mi Choi; Chulmin Park; Jae-Cheol Kwon; Si-Hyun Kim; Sun Hee Park; Jung-Hyun Choi; Jin-Hong Yoo; Wan-Shik Shin
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

Review 10.  Neonatal sepsis due to coagulase-negative staphylococci.

Authors:  Elizabeth A Marchant; Guilaine K Boyce; Manish Sadarangani; Pascal M Lavoie
Journal:  Clin Dev Immunol       Date:  2013-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.